Imperva (NASDAQ:IMPV) Upgraded at BidaskClub

Imperva (NASDAQ:IMPV) was upgraded by equities research analysts at BidaskClub from a “hold” rating to a “buy” rating in a note issued to investors on Friday, October 19th.

IMPV has been the topic of several other reports. Royal Bank of Canada reaffirmed a “buy” rating and set a $62.00 target price on shares of Imperva in a research report on Friday, July 27th. Zacks Investment Research raised Imperva from a “hold” rating to a “buy” rating and set a $62.00 target price on the stock in a research report on Friday, October 12th. Macquarie lowered Imperva from an “outperform” rating to a “neutral” rating and set a $55.00 target price on the stock. in a research report on Thursday, October 11th. Stifel Nicolaus reduced their target price on Imperva from $50.00 to $48.00 and set a “buy” rating on the stock in a research report on Friday, July 27th. Finally, Morgan Stanley raised Imperva from an “underweight” rating to an “equal weight” rating and set a $56.00 target price on the stock in a research report on Thursday, October 11th. Ten analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Imperva has an average rating of “Hold” and an average price target of $56.37.

Shares of IMPV stock traded down $0.06 during mid-day trading on Friday, hitting $56.00. The stock had a trading volume of 478,564 shares, compared to its average volume of 1,556,334. Imperva has a 12-month low of $37.17 and a 12-month high of $57.65.

Imperva (NASDAQ:IMPV) last issued its earnings results on Wednesday, October 31st. The software maker reported $0.43 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.18 by $0.25. Imperva had a negative return on equity of 5.62% and a negative net margin of 8.00%. The business had revenue of $91.63 million during the quarter, compared to analysts’ expectations of $89.24 million. As a group, equities analysts forecast that Imperva will post -1.06 EPS for the current year.

Several large investors have recently bought and sold shares of the stock. BlackRock Inc. increased its stake in Imperva by 2.2% during the third quarter. BlackRock Inc. now owns 2,414,804 shares of the software maker’s stock worth $112,167,000 after acquiring an additional 52,163 shares during the last quarter. RGM Capital LLC raised its stake in Imperva by 0.8% in the second quarter. RGM Capital LLC now owns 1,777,212 shares of the software maker’s stock valued at $85,750,000 after buying an additional 14,045 shares in the last quarter. Rothschild Asset Management Inc. raised its stake in Imperva by 18.4% in the second quarter. Rothschild Asset Management Inc. now owns 594,441 shares of the software maker’s stock valued at $28,682,000 after buying an additional 92,349 shares in the last quarter. Bank of America Corp DE raised its stake in Imperva by 1.2% in the second quarter. Bank of America Corp DE now owns 528,022 shares of the software maker’s stock valued at $25,478,000 after buying an additional 6,443 shares in the last quarter. Finally, Legal & General Group Plc increased its position in shares of Imperva by 27.9% during the second quarter. Legal & General Group Plc now owns 519,725 shares of the software maker’s stock worth $25,077,000 after purchasing an additional 113,280 shares in the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

About Imperva

Imperva, Inc engages in the development, market, sale, and support of cyber security solutions that protect business critical data and applications in the cloud or on premises worldwide. The company's SecureSphere product line provides database, file, and Web application security in various data centers, including on-premises data centers, as well as in private, public, and hybrid cloud computing environments.

Featured Article: Initial Public Offering (IPO)

Analyst Recommendations for Imperva (NASDAQ:IMPV)

Receive News & Ratings for Imperva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply